Initial supplementary dose of dolutegravir in second-line antiretroviral therapy: a noncomparative, double-blind, randomized placebo-controlled trial
<p><strong>Background:</strong> Dolutegravir concentrations are reduced by efavirenz induction effect necessitating twice-daily dolutegravir dosing when coadministered. Efavirenz induction persists for several weeks after stopping, which could potentially select for dolutegravir re...
Hlavní autoři: | Zhao, Y, Griesel, R, Omar, Z, Simmons, B, Hill, A, van Zyl, G, Keene, C, Maartens, G, Meintjes, G |
---|---|
Médium: | Journal article |
Jazyk: | English |
Vydáno: |
Oxford University Press
2023
|
Podobné jednotky
-
Recycling tenofovir in second-line antiretroviral treatment with dolutegravir: outcomes and viral load trajectories to 72 weeks
Autor: Keene, CM, a další
Vydáno: (2023) -
Virologic efficacy of tenofovir, lamivudine and dolutegravir as second-line antiretroviral therapy in adults failing a tenofovir-based first-line regimen
Autor: Keene, CM, a další
Vydáno: (2021) -
Standard-dose versus double-dose dolutegravir in HIV-associated tuberculosis in South Africa (RADIANT-TB): a phase 2, non-comparative, randomised controlled trial
Autor: Griesel, R, a další
Vydáno: (2023) -
AntiRetroviral Therapy In Second-line: investigating Tenofovir-lamivudine-dolutegravir (ARTIST): protocol for a randomised controlled trial
Autor: Zhao, Y, a další
Vydáno: (2021) -
Case report: Emergence of dolutegravir resistance in a patient on second-line antiretroviral therapy
Autor: Kairoonisha Mahomed, a další
Vydáno: (2020-07-01)